Early beta-blocker therapy improves in-hospital mortality of patients with non-ST-segment elevation myocardial infarction - a meta-analysis.

[1]  S. Noble,et al.  Should We Be Using Upstream Beta-Blocker Therapy for Acute Myocardial Infarction? , 2021, Current Cardiology Reports.

[2]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[3]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[4]  O. Ziff,et al.  Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment , 2020, BMC Medicine.

[5]  Julian Pt Higgins,et al.  Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments , 2020, Research synthesis methods.

[6]  E. Oliver,et al.  Beta-blockers: Historical perspective and mechanisms of action. , 2019, Revista espanola de cardiologia.

[7]  V. Fuster,et al.  Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled meta-analysis of randomized clinical trials , 2019, European heart journal. Acute cardiovascular care.

[8]  R. Giugliano,et al.  The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study , 2018, Cardiovascular Drugs and Therapy.

[9]  F. Gaita,et al.  The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS CardioGroup I): A randomized controlled trial. , 2018, International journal of cardiology.

[10]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[11]  J. Ferrières,et al.  Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015 , 2017, Circulation.

[12]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[13]  Jelle J Goeman,et al.  Plea for routinely presenting prediction intervals in meta-analysis , 2016, BMJ Open.

[14]  V. Fuster,et al.  Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. , 2016, Journal of the American College of Cardiology.

[15]  P. V. von Hippel,et al.  The heterogeneity statistic I2 can be biased in small meta-analyses , 2015, BMC Medical Research Methodology.

[16]  V. Fuster,et al.  Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). , 2014, Journal of the American College of Cardiology.

[17]  V. Fuster,et al.  Early intravenous beta-blockers in patients with acute coronary syndrome--a meta-analysis of randomized trials. , 2013, International journal of cardiology.

[18]  W. Gibler,et al.  Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome. , 2009, American Journal of Cardiology.

[19]  W. Gibler,et al.  Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. , 2007, The American journal of medicine.

[20]  K. Eagle,et al.  Patterns of use and potential impact of early beta-blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events. , 2006, American heart journal.

[21]  Robert H Christenson,et al.  Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. , 2002, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[22]  Dwight Lemon,et al.  Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .

[23]  T Greco,et al.  Review Article , 2022 .

[24]  R. Norris.  Beta blockers and infarct size. , 1986, Journal of molecular and cellular cardiology.

[25]  Johan Herlitz,et al.  Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. , 1985, European heart journal.

[26]  S. Goldstein.  The Beta-Blocker Heart Attack Trial in perspective. , 1983, Cardiology.